ReviewFrontiers in immunology2026
Follicular development impairment in polyendocrine metabolic ovarian syndrome: multidimensional pathophysiological networks and frontier therapeutic targets.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS) is a prevalent endocrine-metabolic disorder characterised by follicular arrest, anovulation, and elevated androgen levels. This review transcends single-dimensional analyses of PMOS pathology from neuroendocrine or metabolic perspectives, proposing an integrated multi-layered network model to systematically elucidate the pathological mechanisms underlying follicular arrest. Post-pubertal dysfunction of the hypothalamic-pituitary-ovarian axis interacts with systemic metabolic dysregulation, jointly establishing an ovarian microenvironment characterised by hyperandrogenism, hyperinsulinaemia, and chronic inflammation. This environment further induces self-reinforcing vicious cycles within follicles, manifesting as impaired granulosa-oocyte communication, immunometabolic reprogramming (e.g., M1 macrophage polarisation), and organelle stress (including mitochondrial dysfunction and endoplasmic reticulum stress). This localised cycle is consolidated and amplified by higher-level regulatory factors-including developmental epigenetic programming, the gut-brain-ovary axis, and circadian rhythms-ultimately establishing a pathologically entrenched state. Finally, this network-based understanding informs future research pathways, focusing on how emerging strategies-such as multi-omics integration, artificial intelligence, and stem cell secretome studies-can advance phenotype-directed precision interventions. This review aims to provide a systematic, dynamic theoretical framework for understanding the complex pathogenesis of PMOS and its potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.